首页> 美国卫生研究院文献>Aging (Albany NY) >Lysine-specific histone demethylase 1B (LSD2/KDM1B) represses p53 expression to promote proliferation and inhibit apoptosis in colorectal cancer through LSD2-mediated H3K4me2 demethylation
【2h】

Lysine-specific histone demethylase 1B (LSD2/KDM1B) represses p53 expression to promote proliferation and inhibit apoptosis in colorectal cancer through LSD2-mediated H3K4me2 demethylation

机译:特异性特异性组蛋白去甲基酶1B(LSD2 / KDM1B)抑制P53表达通过LSD2介导的H3K4ME2去甲基化促进扩散和抑制结肠直肠癌的凋亡

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Epigenetic alterations have been reported to play critical roles in the development of colorectal cancer (CRC). However, the biological function of the lysine-specific histone demethylase 1B (LSD2/KDM1B) in CRC is not well understood. Therefore, we investigated the characteristics of LSD2 in CRC. We observed significant upregulation of LSD2 in CRC tissue compared to that in normal colorectal tissue. LSD2 promotes CRC cell proliferation and inhibits cell apoptosis through cell cycle regulation, promoting CRC progression both in vitro and in vivo. We found that LSD2 performs these functions by inhibiting the pathway. Finally, we found that LSD2 directly binds to p53 and represses p53 expression via H3K4me2 demethylation at the promoter. Our results revealed that LSD2 acts as an oncogene by binding and inhibiting p53 activity in CRC. Thus, LSD2 may be a new molecular target for CRC treatment.
机译:据报道,表观遗传改变在结直肠癌(CRC)的发展中发挥着关键作用。然而,CRC中赖氨酸特异性组蛋白脱甲基酶1B(LSD2 / KDM1B)的生物学功能尚不清楚。因此,我们研究了CRC中LSD2的特征。与正常结直肠组织相比,我们观察到CRC组织中LSD2的显着上调。 LSD2通过细胞周期调节促进CRC细胞增殖并抑制细胞凋亡,在体外和体内促进CRC进展。我们发现LSD2通过抑制通路来执行这些功能。最后,我们发现LSD2直接结合P53并通过启动子的H3K4ME2去甲基化抑制p53表达。我们的研究结果表明,LSD2通过结合和抑制CRC中的P53活性作为癌基因。因此,LSD2可以是CRC处理的新分子靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号